Use of dermal equivalent and skin equivalent models for identifying phototoxic compounds in vitro.
Phototoxicity inducing in vivo photoirritation, a reversible inflammatory reaction of the skin after chemical contact and UVA radiation exposure, is increasingly observed as a side effect associated with the use of both cosmetics and systemic drugs. In order to systematically screen for the phototoxic potential of new compounds, we propose two three-dimensional models suitable for in vitro testing: a dermal equivalent (DE) and a skin equivalent (SE) model. The DE model includes a collagen-glycosaminoglycans-chitosan porous matrix populated by normal human fibroblasts. The SE model is made by seeding normal human keratinocytes onto the DE, leading to a fully differentiated epidermis. The objectives of this pilot study are: 1) to compare the deleterious effects of UVA radiation on the two models and 2) to evaluate to what extent the in vitro results can predict the in vivo phototoxicity caused by well-known photoirritant compounds, included in the COLIPA validation phototoxicity reference chemical list. Dilutions of thiourea, sulisobenzone, promethazine, chlorpromazine and tetracycline were applied (20 microliters) onto DEs and SEs (n = 6) and incubated for 1 h (or 15 h) at 37 degrees C. Irradiated samples received 3 J/cm2 UVA. The 24 h post-irradiation residual cellular viability was measured using the MTT test on treated and untreated tissues and IL-1 alpha release measurement in collected SE culture media. A concordance in terms of photoirritant/non-photoirritant was obtained between the in vivo data and the in vitro results, suggesting that the DE and the SE models could be integrated, after a complete validation study, into a protocol for in vitro testing of the photoirritant potential of new molecules.
Augustin
C
C
Laboratoire des Substituts Cutanés, (CNRS-UPR 412), Hôpital Edouard Herriot, Lyon, France.
Collombel
C
C
Damour
O
O
D018926:Anti-Allergic Agents / Q000494:pharmacology; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D000932:Antiemetics / Q000494:pharmacology; D013956:Antithyroid Agents / Q000494:pharmacology; D001577:Benzophenones / Q000494:pharmacology; D001704:Biopolymers; D002470:Cell Survival; D002478:Cells, Cultured; D002686:Chitin / Q000031:analogs & derivatives; D048271:Chitosan; D002746:Chlorpromazine / Q000494:pharmacology; D003094:Collagen; D003358:Cosmetics / Q000009:adverse effects; D003470:Culture Media; D017484:Dermatitis, Phototoxic / Q000209:etiology*; D064420:Drug-Related Side Effects and Adverse Reactions; D000078404:Epidermal Cells; D005347:Fibroblasts / Q000187:drug effects / Q000528:radiation effects; D005544:Forecasting; D006025:Glycosaminoglycans; D006801:Humans; D007375:Interleukin-1 / Q000032:analysis; D007509:Irritants / Q000009:adverse effects*; D015603:Keratinocytes / Q000187:drug effects / Q000528:radiation effects; D010787:Photosensitivity Disorders / Q000139:chemically induced*; D010865:Pilot Projects; D011398:Promethazine / Q000494:pharmacology; D015203:Reproducibility of Results; D012867:Skin / Q000187:drug effects / Q000528:radiation effects; D013473:Sunscreening Agents / Q000494:pharmacology; D013752:Tetracycline / Q000494:pharmacology; D013890:Thiourea / Q000494:pharmacology; D014466:Ultraviolet Rays / Q000009:adverse effects
D018926:Anti-Allergic Agents; D000900:Anti-Bacterial Agents; D000932:Antiemetics; D013956:Antithyroid Agents; D001577:Benzophenones; D001704:Biopolymers; D003358:Cosmetics; D003470:Culture Media; D006025:Glycosaminoglycans; D007375:Interleukin-1; D007509:Irritants; D013473:Sunscreening Agents; D002686:Chitin; C009361:sulisobenzone; D003094:Collagen; D048271:Chitosan; D013752:Tetracycline; D011398:Promethazine; D013890:Thiourea; D002746:Chlorpromazine